Reversible Fanconi syndrome in a pediatric patient on deferasirox

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 674-676

  Rheault, Michelle N ^a   Bechtel, Heather ^a   Neglia, Joseph P ^a   Kashtan, Clifford E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

thalassemia; Iron chelation; Iron overload; Kidney; Proximal tubular dysfunction

Indexed keywords

ALBUMIN; ARGININE; BETA 2 MICROGLOBULIN; CALCIUM; CARBON DIOXIDE; CREATININE; DEFERASIROX; DEFEROXAMINE; FERRITIN; GLUCOSE; GLYCINE; LEUCINE; MAGNESIUM; NITROGEN; PHOSPHORUS; POTASSIUM; SODIUM; TYROSINE; UREA;

AMINO ACID URINE LEVEL; AMINOACIDURIA; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CARBON DIOXIDE BLOOD LEVEL; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ERYTHROCYTE TRANSFUSION; FANCONI RENOTUBULAR SYNDROME; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPERCALCIURIA; HYPOKALEMIA; IRON CHELATION; LOW BACK PAIN; MAGNESIUM BLOOD LEVEL; MALE; METABOLIC ACIDOSIS; NAUSEA; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCHOOL CHILD; SODIUM BLOOD LEVEL; SOUTH ASIA; THALASSEMIA MAJOR; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WALKING DIFFICULTY;

BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; ERYTHROCYTE TRANSFUSION; FANCONI SYNDROME; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; TRIAZOLES;

EID: 79551617114     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22711     Document Type: Article

References (16)

1. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.
2. De Sanctis V, Roos M, Gasser T, et al. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab 2006;19:471-480.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
4. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462.
5. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009;52:616-620.
6. Smolkin V, Halevy R, Levin C, et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 2008;23:1847-1851.
7. Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 2000;15:109-112.
8. Koliakos G, Papachristou F, Koussi A, et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003;25:105-109.
9. Sumboonnanonda A, Malasit P, Tanphaichitr VS, et al. Renal tubular function in beta-thalassemia. Pediatr Nephrol 1998;12:280-283.
10. Kalman S, Atay AA, Sakallioglu O, et al. Renal tubular function in children with beta-thalassemia minor. Nephrology (Carlton) 2005;10:427-429.
11. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006;2:80-91.
12. Papadopoulos N, Vasiliki A, Aloizos G, et al. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major (January). Ann Pharmacother 2009;44:219-221.
13. Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis 2009;54:931-934.
14. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol 2010;85:132-134.
15. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-1076.
16. Koren G, Kochavi-Atiya Y, Bentur Y, et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991;54:371-375.